Evgen Pharma plc (EVG:LSE) Investor Relations Material

Overview

Eaton Vance Management has launched and managed a closed-ended fixed income mutual fund known as the Eaton Vance Short Duration Diversified Income Fund. Focusing on fixed income markets in the United States, the fund invests primarily in various financial assets, including secured floating-rate loans, mortgage-backed securities, and debt obligations of foreign governmental and corporate issuers. With an average credit quality of BBB– or greater and a duration of 1.76 years, the fund maintains a diversified portfolio that benchmarks its performance against the S&P/LSTA Leveraged Loan Index. Originally named the Eaton Vance Low Duration Diversified Income Fund, it was established on February 28, 2005, and is domiciled in the United States.

Frequently Asked Questions

What is Evgen Pharma plc's ticker?

Evgen Pharma plc's ticker is EVG

What exchange is Evgen Pharma plc traded on?

The company's shares trade on the LSE stock exchange

Where are Evgen Pharma plc's headquarters?

They are based in Nether Alderley, England

How many employees does Evgen Pharma plc have?

There are 1-10 employees working at Evgen Pharma plc

What is Evgen Pharma plc's website?

It is https://evgen.com/

What type of sector is Evgen Pharma plc?

Evgen Pharma plc is in the Healthcare sector

What type of industry is Evgen Pharma plc?

Evgen Pharma plc is in the Biotechnology industry

Who are Evgen Pharma plc's peers and competitors?

The following five companies are Evgen Pharma plc's industry peers:

- Ampio Pharmaceuticals

- PDS Biotechnology

- Achillion Pharmaceuticals Inc.

- Avid Bioservices

- Protagonist Therapeutics, Inc.